JPRN-UMIN000009628已完成2 期
Clinical trial of postoperative chemotherapy with TS-1 in recurrent high-risk cases with oral squamous cell carcinoma - Clinical trial of postoperative chemotherapy with TS-1 in recurrent high-risk cases with oral squamous cell carcinoma
Department of Clinical Oral Oncology, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences0 个研究点目标入组 90 人开始时间: 2012年12月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Simultaneous or metachronous (within 5 years) double cancers 2) Administration contraindication of TS-1 3) Serious postoperative complications 4) Watery diarrhea 5) One or more of following comorbid disorder Poor controlled diabetes, poor controlled hypertension, hepatic cirrhosis, hepatic insufficiency, renal failure, interstitial pneumonia, fibroid lung, severe pulmonary emphysema, active infectious disease, heart failure for not more than 6 months, cardiac infarction, severe aberration of electrocardiogram 6) Pleural effusion, pericardiac effusion, or ascites to be drained. 7) Continuous flucytosine, phenytoin, and warfarin potassium treatment 8) Severe drug allergy 9) Psychiatric disease 10) Women during pregnancy, possible pregnancy, or breast-feeding 11) Men with making pregnant 12) Cases judged to be inappropriate by attending physician
研究者
相似试验
已完成
2 期
Phase II trial of perioperative chemotherapy with cisplatin and dose dense paclitaxel in patients with stage IB2,IIA2 orIIB uterine cervical cancer SGSG014Cervical cancer patients with clinical stage IB2, IIA, IIBJPRN-UMIN000009643Sankai Gynecology Study Group50
已完成
不适用
Phase II trial of perioperative chemotherapy with cisplatin and dose dense paclitaxel in patients with stage Ib2-IIb uterine cervical cancer (SGSG013)JPRN-UMIN000006440Sankai Gynecology Study Group50
尚未招募
不适用
A phase II trial of preoperative chemotherapy with capecitabine plus short-course radiotherapy for resectable T3 rectal cancerJPRN-UMIN000016518Meiwa Hospital60
进行中（未招募）
1 期
A phase II clinical trial for patients with node-negative stage I-II intermediate or high risk endometrial cancer where the patients will be divided into 2 groups; chemotherapy after surgery versus observation only.ode-negative stage I-II intermediate or high risk endometrial cancerMedDRA version: 21.0Level: PTClassification code 10014738Term: Endometrial cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10014739Term: Endometrial cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023081-52-DEDanish Gynaecological Cancer Group240
进行中（未招募）
1 期
A phase II clinical trial for patients with node-negative stage I-II intermediate or high risk endometrial cancer where the patients will be divided into 2 groups; chemotherapy after surgery versus observation only.ode-negative stage I-II intermediate or high risk endometrial cancerMedDRA version: 21.0Level: PTClassification code 10014738Term: Endometrial cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10014739Term: Endometrial cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023081-52-BEDanish Gynaecological Cancer Group240